Additional file 12 of Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities

Additional file 12: Table S10. Profiles of KMT2D mutations and immune markers in POG and MSK-IMPACT cases. A. POG solid cancer clinical data and immune marker profiles. OS: overall survival. censor_status: 1-living, 2-deceased. Fpkm: fragments per kilobase of transcript per million mapped reads. B_cells_naive to absolute_score_sig_score columns are immune cell composition score outputs from Cibersort. PredictIO_score: immune checkpoint response score (see Methods section). B. MSK-IMPACT cohort overall survival and TMB obtained from Samstein et al. (13), and MSI and KMT2D status (see Methods section).

附加文件12：表S10。POG与MSK-IMPACT队列中组蛋白赖氨酸甲基转移酶2D（KMT2D）突变及免疫标志物特征。A. POG实体瘤临床数据及免疫标志物特征：总生存期（overall survival, OS）；删失状态：1为存活，2为死亡；FPKM（每百万映射读数的每千碱基转录本片段数，Fragments Per Kilobase of transcript per Million mapped reads）：从初始B细胞（B_cells_naive）至特征绝对评分（absolute_score_sig_score）的列均为Cibersort输出的免疫细胞组成评分；PredictIO评分：免疫检查点应答评分（详见方法部分）。B. MSK-IMPACT队列的总生存期、取自Samstein等(13)的肿瘤突变负荷（Tumor Mutational Burden, TMB），以及微卫星不稳定性（Microsatellite Instability, MSI）与KMT2D状态（详见方法部分）